Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 162

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 162
---
, and is also participating as an investor in the PIPE Financing. Later on December 19, 2024, Aadi and WuXi Biologics entered into the License Agreement and Aadi and the PIPE Financing investors entered into the Subscription Agreement. A press release regarding the execution of the License Agreement and the Subscription Agreement, the appointment of Dr. Zhao to Aadi’s board of directors, and related matters was issued after the close of market that same day. Aadi filed a current report on Form 8-Kwith the SEC announcing such items on December 20, 2024 before market open. Reasons for the PIPE Financing and the License Agreement and Recommendation of the Aadi Board of Directors Aadi’s board of directors unanimously: (i) determined that the Subscription Agreement, the Registration Rights Agreement and the Pre-FundedWarrant, and all the transactions contemplated thereby, including the PIPE Financing, were fair, advisable and in the best interests of Aadi and its stockholders; (ii) approved in all respects the Subscription Agreement, the Registration Rights Agreement, and the Pre-FundedWarrant, and all the transactions contemplated thereby, including the PIPE Financing; (iii) determined that it was advisable and in the bests interests of Aadi and its stockholders to enter into the License Agreement; (iv) approved in all respects the form, terms and provisions of the License Agreement; and (v) recommended that stockholders for “FOR” the PIPE Financing. In the course of taking such actions in favor of the PIPE Financing and the License Agreement, Aadi’s board of directors considered a number of potentially supportive factors in its deliberations including:

| • |     | the extensive business development process undertaken by Aadi’s management team and the Strategic             
 Transaction Committee to identify and evaluate potential in-licensing and acquisition opportunities for Aadi; |

| • |     | the extensive due diligence process undertaken by Aadi’s management team and its advisors, under the              
 oversight of Aadi’s board of directors and the Strategic Transaction Committee, with respect to the ADC Programs; |

| • |     | the reputation and expertise of WuXi Biologics and Hangzhou DAC; |

| • |     | the assessment of Aadi’s board of directors of the potential long-term value to stockholders of the License                  
 Agreement and the ADC Programs, as compared to Aadi’s estimated dissolution value following the sale of the FYARRO business; |

| • |     | the fact that multiple ADC assets are included in the ADC Programs, providing